Novo Undercuts Lilly’s Obesity Drug Price, Now Cheaper Than Car Payment Just before the US cash session, Novo Nordisk A/S announced it will slash prices on Wegovy and Ozempic in a direct challenge to Eli Lilly’s obesity drug, aiming to regain market share. The announcement comes just weeks after President Trump finalized a deal with Novo and Lilly to reduce costs as part of the administration’s affordability push ahead of next year’s midterms. Beginning immediately, introductory doses of Wegovy and Ozempic will cost just $199 per month for the first two months for cash-pay patients. After that, the price rises to… — Continue at ZeroHedge News : Read More
